ESMO 2025
The ESMO Congress is a highly influential global oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.
ESMO 2025 will be a place where groundbreaking discoveries, cutting-edge treatments and a collaborative approach converge to shape the future of cancer care.
You will be able to learn from internationally renowned experts, engage in thought-provoking discussions and connect with fellow oncology professionals that are driving advancements in diagnosis, treatment and survivorship.
ESMO 2025: Colon cancer DNA detectable in blood can guide chemo decisions: study
ESMO 2025: Roundup of MSK's research, including lung and pancreatic cancer treatments
ESMO 2025: Combination of immunotherapy and targeted therapy improves survival for patients with advanced colorectal cancer
ESMO 2025: Blood test guides post-surgical immunotherapy for muscle-invasive bladder cancer
ESMO 2025: DNA shed by colon cancers may help personalise postsurgical treatment
ESMO 2025: Research targets treatment resistance in neuroendocrine tumours
ESMO 2025: Chemo combination boosts overall survival in patients with EGFR-mutant NSCLC
ESMO 2025: Immunotherapy after surgery shows potential in preventing the spread of aggressive skin cancer
ESMO 2025: New generation of antibody-drug conjugates shows promise in early-stage disease
ESMO 2025: Novel treatment combination improves progression-free survival in metastatic, oestrogen-receptor-positive HER-2-negative breast cancer
ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma
ESMO 2025: Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer
ESMO 2025: ADC improves outcomes for patients with advanced triple-negative breast cancer who are ineligible for immune checkpoint inhibitors
ESMO 2025: Drug combo cuts risk of death in advanced prostate cancer by 40%
ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer
ESMO 2025: Men with BRCA1 and BRCA2 gene mutations should get annual prostate cancer screening - ICR
ESMO 2025: Thymic health linked to immunotherapy response
Post-treatment exercise programme improves survival for stage II/III colon cancer
Latest in bladder cancer from the second half of 2025
I-DXd shows strong brain metastasis responses in extensive-stage small cell lung cancer with manageable safety
Tarlatamab for SCLC: Subgroup analysis shows benefit regardless of previous chemo or anti-PD-(L)1 use
Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC
Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo
Temab-A plus bevacizumab shows promising response rates in advanced colorectal cancer
ESMO 2025: Latest developments in endometrial cancer
PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma
ESMO 2025: Highlights and analysis
Tarlatamab plus chemo-IO shows promising efficacy in extensive stage SCLC
ESMO 2025: Precision medicine in bladder cancer
ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer
Neoadjuvant TAR-200 plus cetrelimab improves PCR in muscle-invasive bladder cancer
Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer
ESMO 2025: Prostate highlights
ESMO 2025: Bladder cancer highlights
ESMO 2025: Renal highlights
Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC
177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC
ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable outcomes in stage III colon cancer
Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity
ctDNA-guided adjuvant atezolizumab improves OS in MIBC
Best practice in precision medicine for prostate cancer
Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival
IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma
Zanzalintinib plus atezolizumab improves survival in refractory mCRC
Trastuzumab deruxtecan demonstrates advance in treatment for HER2-positive gastric cancer
Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC
Durvalumab with BCG and maintenance therapy improves disease-free survival in high-risk NMIBC
Perioperative enfortumab vedotin plus pembro improves survival and pCR in cisplatin-ineligible MIBC
ESMO 2025: Latest in EGFR mutant NSCLC
Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine in high-risk HER2+ early breast cancer
Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource-constrained settings
Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer
Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC
Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma
Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC
MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection
Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors
Tarlatamab shows manageable safety profile with fewer toxicities than chemo in 2L SCLC
Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside others
Taletrectinib shows efficacy and tolerability in advanced ROS1+ NSCLC previously treated with entrectinib